Business
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved
About this update from Novavax, Inc.
[{"type":"text","content":"\n \n Total revenue of $70 million in the third quarter of 2025\n \n \n Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on marketing authorization transfers\n \n \n Sanofi reported preliminary positive immunogenicity and safety Phase 1/2 data for Nuvaxovid\n ™\n in combination with both Fluzone High-Dose and Flublok\n \n \n Sanofi received BARDA grant for pandemic influenza vaccine candidate using Novavax's Matrix-M® adjuvant\n \n \n Maryland site consolidation transactions resulted in $60 million cash proceeds and approximately $230 million in expected future cost savings\n \n \n Raises Full Year 2025 Revenue Framework and Affirms Financial Guidance\n \n \n C\n ompany to host conference\n call today at 8:30 a.m. ET\n \n \n \n GAITHERSBURG, Md., Nov. 6, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025.\n \"We have continued the steady transformation of Novavax and are proud of our progress this quarter,\" said John C. Jacobs, President and Chief Executive Officer, Novavax. \"This year we have relaunched the Company with a focus on R&D and partnerships intended to position us well for long-term growth and profitability.\"\n \n Third Quarter 2025 and Recent Highlights\n \n \n \n Key Highlights \n \n \n \n \n Strategic Priority #1: Optimize our Sanofi Partnership\n \n \n \n Continued successful execution of Sanofi partnership with $225 million in milestones earned year-to-date, including $50 million earned in the fourth quarter of 2025, upon marketing authorization transfers for E.U. and U.S. markets.\n In October 2025, Sanofi reported preliminary positive immunogenicity and safety Phase 1/2 data for Nuvaxovid™ in combination with both Fluzone High-Dose and Flublok. Both programs have received Fast Track designation from the U.S. Food and Drug Administration (FDA).\n In August 2025, the FDA approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19 in individuals 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. Nuvaxovid was approved with an extended shelf life of six months in a pre-filled syringe formulati...